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Supplementary Experimental Section 
Chemistry. 
1
H and 
13
C-NMR spectra were recorded on a Bruker Avance 300 at 300 and 75 MHz 
respectively, using SiMe4 as the internal standard. Low resolution mass spectra were recorded with a 
Finnigan-Mat TSQ-700. Melting points were determined with a capillary apparatus (Büchi 540). Flash 
column chromatography was performed on silica gel (Merck Kieselgel 60, 230-400 mesh ASTM); PE 
stands for 40-60 petroleum ether. The progress of the reactions was followed by thin layer 
chromatography (TLC) on 5×20 cm plates with a layer thickness of 0.2 mm. Anhydrous magnesium 
sulfate was used as the drying agent for the organic phases. Organic solvents were removed under 
vacuum at 30 °C. Elemental analyses (C, H, N) were performed by REDOX (Monza), and the results are 
within (0.4% of the theoretical values. Compounds 7a,
1
 7b,
2
 7c
3
, 7d
3
, 10
4
 and 13
5
 were obtained as 
described elsewhere. 
General procedure for the preparation of 8a-d. To a solution of the appropriate alcohol (2.5 mmol) 
and chloromethylchloroformate (0.25 mL, 2.7 mmol) in dry CH2Cl2 (15 mL), stirred at -15 °C, a 
solution of Py (0.22 mL, 2.7 mmol) in dry CH2Cl2 (10 mL) was added dropwise. At the end of the 
addition the ice-salt bath was removed and the reaction mixture was allowed to reach room temperature. 
After 15 min the solvent was removed and obtained oil was purified by flash chromatography. 
Chromatographic eluents and yields of the products were as follow. 
Chloromethyl-3-nitrooxypropyl carbonate (8a). Eluent (PE/CH2Cl2 7/3 v/v); colourless oil; yield 
83%. 
1
H-NMR (CDCl3)  2.15 (qi, 2H, -CH2CH2ONO2), 4.35 (t, 2H, -OCH2CH2-), 4.58 (t, 2H, 
-CH2ONO2), 5.74 (s, 2H, -CH2Cl). 
13
C-NMR (CDCl3)  26.3, 64.9, 69.1, 72.3, 153.2. 
Chloromethyl-5,6-dinitrooxypropyl carbonate (8b). Eluent (PE/CH2Cl2 1/1 v/v); colourless oil; 
yield 80%. 
1
H-NMR (CDCl3)  4.44 (dd, 1H, -CHHO-), 4.56 – 4.70 (m, 2H, -CHHONO2 + , -CHHO-), 
4.81 (dd, 1H, , -CHHONO2), 5.48 – 5.54 (m, 1H, -CHONO2), 5.72 – 5.77 (m, 2H, -CH2Cl). 
13
C-NMR 
(CDCl3)  64.6, 68.2, 72.6, 75.6, 152.9. 
 S3 
Chloromethyl-4-(3-nitrooxypropyl)phenyl carbonate (8c). Eluent (PE/CH2Cl2 8/2 v/v); colourless 
oil, which solidified on standing in freezer; yield 75%. 
1
H-NMR (CDCl3)  2.05 (m, 2H, 
-CH2CH2ONO2), 2.75 (t, 2H, -CH2CH2CH2ONO2), 4.45 (t, 2H, -CH2ONO2), 5.82 (s, 2H, -CH2Cl), 7.13 
– 7.26 (m, 4H, C6H4). 
13
C-NMR (CDCl3)  28.3, 31.1, 72.1, 72.5, 120.9, 129.5, 138.6, 149.2, 152.1. 
4-(2,3-Bis(nitrooxy)propyl)phenyl chloromethyl carbonate (8d). Eluent (PE/CH2Cl2 6/4 v/v); 
yellowish oil; yield 50%. 
1
H-NMR (CDCl3)  2.99 – 3.14 (m, 2H, -CH2CH-), 4.44 (dd, 1H, 
-CHHONO2), 4.73 (dd, 1H, -CHHONO2), 5.40 – 5.47 (m, 1H, -CHONO2), 5.82 (s, 2H, -CH2Cl), 7.20 – 
7.30 (m, 4H, C6H4). 
13
C-NMR (CDCl3)  34.9, 70.0, 72.6, 79.2, 121.5, 130.5, 132.6, 150.2, 151.9. MS 
EI: 350 (M)
+
. 
5-(4-(2-Hydroxyethoxy)phenyl)-3H-1,2-dithiole-3-thione (12). To a solution of Ph3P (0.28 g, 1.1 
mmol) in dry THF (10 mL), stirred under positive nitrogen pressure at -15 °C, DIAD (0.22 mL, 1.1 
mmol) was added. Reaction mixture was stirred for 15 min, until white precipitate formed and 10 (0.20 
g, 0.90 mmol) was added, followed by 2-(tetrahydropyran-2-yloxy)ethanol (0.13 g, 0.90 mmol). The 
resulting mixture was stirred for 24 hours at room temperature, then was poured in H2O (10 mL) and 
extracted with Et2O (3 × 10 mL). The combined organic layers were washed with brine, dried, filtered 
and concentrated under reduced pressure. The crude product was purified by flash chromatography 
(PE/acetone 9/1 v/v) to give 5-(4-(2-(tetrahydropyran-2-yloxy)ethoxy)phenyl)-3H-1,2-dithiole-3-thione 
(11) as a reddish-brown oil; yield 70 %.
1
H-NMR (CDCl3)  1.52-1.89 (m, 6H, 3CH2 pyran), 3.51-3.58 
(m, 1H), 3.81-4.25 (m, 5H), (CH2Opyran, -OCH2CH2O-), 4.70-7.72 (m, 1H, -OCHO-), 7.02 (d, 2H, 
C6H4), 7.40 (s, 1H, C3S3H), 7.62 (d, 2H, C6H4). 
13
C-NMR (CDCl3)  19.4, 25.4, 30.5, 62.3, 65.6, 67.8, 
99.1, 115.5, 124.2, 128.6, 134.6, 162.3, 173.1, 215.1. MS (CI) m/z 355 (M+1)
+
. 
11 (0.44 g; 1.20 mmol) was dissolved in MeOH (15 mL) and a catalytic amount of PPTS was added. 
The resulting mixture was heated at 55°C for 2 h, then concentrated under reduced pressure. The crude 
product was purified by flash chromatography (PE/acetone 6/4 v/v) to give a reddish solid, which was 
recrystallized from EtOH to give the title compound as a yellowish-orange solid; yield 40 %; m.p. 117.5 
°C (from EtOH). 
1
H-NMR (CDCl3)  2.12 (sbr, 1H, OH), 4.02 (t, 2H), 4.16 (t, 2H)(-OCH2CH2OH), 
 S4 
7.00 (d, 2H, C6H4), 7.39 (s, 1H, C3S3H), 7.61 (d, 2H, C6H4). 
13
C-NMR (CDCl3)  61.2, 69.6, 115.5, 
124.5, 128.6, 134.7, 162.0, 172.9, 215.1. MS (CI) m/z 271 (M+1)
+
. 
General procedure for the preparation of 9a-d, 14. To a solution of acetylsalicylic acid (0.22 g, 1.2 
mmol) in DMF (5 mL) Cs2CO3 (0.20 g, 0.60 mmol) was added and the resulting mixture was vigorously 
stirred for 15 min; then the appropriate chloromethylcarbonate (1.0 mmol) was added and reaction 
mixture was stirred at room temparature for 24 h. The reaction mixture was diluted with Et2O (25 mL) 
and washed with H2O, a saturated solution of NaHCO3 and brine. The organic layer was dried, filtered 
and concentrated under reduced pressure. The crude product so obtained was purified by flash 
chromatography. Chromatographic eluents and yields of the products were as follow. 
[(3-Nitrooxypropyl)carbonyl]oxymethyl 2-(acetyloxy)benzoate (9a). Eluent (PE/EtOAc 9/1 v/v); 
colourless oil; yield 75%. 
1
H-NMR (CDCl3) : 2.12 (qi, 2H, -CH2CH2ONO2), 2.36 (s, 3H, -CH3), 4.31 
(t, 2H, -OCH2CH2-), 4.55 (t, 2H, -CH2ONO2), 5.95 (s, 2H, -OCH2O-), 7.12 (d, 1H), 7.34 (t, 1H), 7.61 (t, 
1H), 8.08 (d, 1H) (C6H4). 
13
C-NMR (CDCl3) : 21.0, 26.3, 64.4, 69.2, 82.2, 121.7, 124.1, 126.2, 132.5, 
134.9, 151.2, 153.8, 162.7, 168.2. MS (CI) m/z 358 (M+1)
+
. Anal. (C14H15NO10): C, H, N. 
([2,3-Bis(nitrooxy)propyl]carbonyl)oxymethyl 2-(acetyloxy)benzoate (9b). Eluent (PE/EtOAc 8/2 
v/v); colourless oil; yield 29%. 
1
H-NMR (CDCl3) : 2.36 (s, 3H, -CH3), 4.39 (dd, 1H, -CHHONO2), 
4.54 (dd, 1H, -CHHONO2), 4.64 (dd, 1H, -CHHO-), 4.80 (dd, 1H, -CHHO-), 5.45-5.51 (m, 1H, 
-CHONO2), 5.97 (s, 2H, -OCH2O), 7.13 (d, 1H), 7.35 (t, 1H), 7.62 (t, 1H), 8.08 (d, 1H) (C6H4). 
13
C-
NMR (CDCl3) : 20.9, 64.3, 68.2, 75.7, 82.5, 121.6, 124.1, 126.3, 132.3, 135.0, 151.2, 153.5, 162.6, 
169.7. MS (CI) m/z 419 (M+1)
+
. Anal. (C14H14N2O13): C, H, N. 
[4-(3-Nitrooxypropyl)phenoxycarbonyl]oxymethyl 2-(acetyloxy)benzoate (9c). Eluent (PE/EtOAc 
8/2 v/v); white solid; m.p. 52.5-53 °C (from iPr2O); yield 64%. 
1
H-NMR (CDCl3) : 2.04 (qi, 2H, 
-CH2CH2ONO2), 2.37 (s, 3H, -CH3), 2.74 (t, 2H, -CH2CH2CH2ONO2), 4.45 (t, 2H, -CH2ONO2), 6.05 (s, 
2H, -OCH2O-), 7.13-7.22 (m, 5H), 7.37 (t, 1H), 7.65 (t, 1H), 8.11 (d, 1H) (2C6H4). 
13
C-NMR (CDCl3) : 
21.0, 28.3, 31.1, 72.1, 82.5, 121.0, 121.7, 124.1, 126.2, 129.5, 132.3, 135.0, 138.4, 149.3, 151.2, 152.7, 
162.7, 169.7. MS (CI) m/z 434 (M+1)
+
. Anal. (C20H19NO10): C, H, N. 
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[4-[2,3-Bis(nitrooxy)propyl]phenoxycarbonyl]oxymethyl 2-(acetyloxy)benzoate (9d). Eluent 
(PE/EtOAc 8/2 v/v); colourless oil; yield 51%.
1
H-NMR (CDCl3)  2.36 (s, 3H, -CH3), 2.97-3.13 (m, 
2H, -CH2CH-), 4.43 (dd, 1H, -CHHONO2), 4.73 (dd, 1H, -CHHONO2), 5.38-5.46 (m, 1H, -CHONO2), 
6.05 (s, 2H, -OCH2O-), 7.13-7.38 (m, 6H), 7.61 (t, 1H), 8.11 (d, 1H) (2C6H4). 
13
C-NMR (CDCl3)  
21.0, 34.9, 70.0, 79.2, 82.5, 121.7, 124.1, 126.2, 130.5, 132.3, 135.0, 150.3, 151.3, 152.5, 162.7, 169.7. 
MS (CI) m/z 495 (M+1)
+
. Anal. (C20H18N2O13): C, H, N. 
(Ethylthiocarbonyl)oxymethyl 2-(acetyloxy)benzoate (14). Eluent (PE/EtOAc 8/2 v/v); colourless oil; 
yield 87%.
1
H-NMR (CDCl3) : 1.33 (t, 3H, -CH2CH3), 2.36 (s, 3H, -CH3), 2.90 (q, 2H, -CH2CH3), 6.00 
(s, 2H, -OCH2O-), 7.13 (d, 1H), 7.35 (t, 1H), 7.60 (t, 1H), 8.07 (d, 1H) (C6H4). 
13
C-NMR (CDCl3) : 
14.8, 21.0, 25.5, 80.5, 121.9, 124.1, 126.1, 132.3, 134.8, 151.2, 162.7, 169.6, 170.8. MS (EI) m/z 298 
(M)
+
. 
General procedure for the preparation of 16a and 16b. SO2Cl2 (0.88 mL, 10.9 mmol) was added 
dropwise to 14 (3.24 g, 10.9 mmol) stirred at 0 °C. The mixture was allowed to reach room temperature 
and stirred for 1 hour. Then the reaction mixture was concentrated under reduced pressure to give 15 as 
colourless oil that was used in the next synthetic step without further purification. 
To a solution of 15 (0.85 g, 3.1 mmol) in CH2Cl2 (30 mL), stirred at -15 °C, a solution of the 
appropriate hydroxy derivative (2.6 mmol) and N-methylmorpholine (0.31 mL, 2.6 mmol) in CH2Cl2 
(30 mL) was added dropwise. The reaction mixture was stirred for 1 hour at -15 °C, then for 24 hours at 
room temperature, then was poured in H2O (20 mL) and extracted with CH2Cl2 (3 × 20 mL). The 
combined organic layers were washed with brine, dried, filtered and concentrated under reduced 
pressure. The crude product was purified by flash chromatography. Chromatographic eluents and yields 
of the products were as follow. 
((4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenoxy)carbonyloxy)methyl 2-acetoxybenzoate (16a). Eluent 
(PE/EtOAc 8/2 v/v); reddish-brown solid, which was recrystallized from EtOH to give the title 
compound as a yellowish-orange solid; yield 30 %; m.p. 103.5-104 °C (from EtOH). 
1
H-NMR (CDCl3) 
 2.37 (s, 3H, -CH3), 6.07 (s, 2H, -OCH2O-), 7.15 (d, 1H, C6H4), 7.33 – 7.40 (m, 4H, 2C6H4 + C3HS3), 
 S6 
7.61 – 7.71 (m, 3H), 8.13 (d, 1H) (2C6H4). 
13
C-NMR (CDCl3)  21.0, 82.6, 121.5, 122.2, 124.1, 126.2, 
128.4, 129.8, 132.3, 135.0, 136.2, 151.3, 151.8, 153.3, 162.6, 169.8, 171.4, 215.5. MS (CI) m/z 463 
(M+1)
+
. Anal. (C20H14O7S3): C, H, N. 
((2-(4-(3-Thioxo-3H-1,2-dithiol-5-yl)phenoxy)ethoxy)carbonyloxy)methyl 2-acetoxybenzoate 
(16b). Eluent (PE/EtOAc 75/25 v/v); reddish-brown solid, which was recrystallized from EtOH to give 
the title compound as a yellowish-orange solid; yield 20 %; m.p. 105 °C (from EtOH).
 1
H-NMR 
(CDCl3)  2.36 (s, 3H, -CH3), 4.28 (t, 2H), 4.58 (t, 2H) (-OCH2CH2O-), 5.98 (s, 2H, -OCH2O-), 6.96 (d, 
2H), 7.13 (d, 1H), 7.33 (t, 1H) (2C6H4), 7.37 (s, 1H, C3HS3), 7.56 – 7.65 (m, 3H), 8.8 (d, 1H) (2C6H4). 
13
C-NMR (CDCl3)  21.0, 65.7, 66.4, 82.3, 115.6, 121.7, 124.1, 124.7, 126.2, 128.6, 132.2, 134.8, 
134.9, 151.2, 153.9, 161.5, 162.6, 169.7, 172.7, 215.2. MS (CI) m/z 507 (M+1)
+
. Anal. (C22H18O8S3): C, 
H, N. 
Evaluation of stability in buffered solutions and in human serum. 
Hydrolysis in acidic medium (pH 1.0) and in phosphate buffer (pH 7.4). A 2 mL aliquot of 0.5 mM 
solution of each compound in DMSO was diluted to 10 mL using HCl 0.1 M to reach pH 1.0 or 
phosphate buffer 50 mM to obtain pH 7.4. The resulting solution was maintained at 37  0.5 °C and at 
appropriate time intervals a 20 L aliquote of reaction solution was analysed by RP-HPLC. All 
experiments were performed in triplicate. 
Hydrolysis in human serum. A solution of each compound (10 mM) in DMSO was added to human 
serum (sterile-filtered from human male AB plasma, Sigma-Aldrich) preheated at 37 °C; the final 
concentration of the compound was 200 M. The resulting solution was incubated at 37  0.5 °C and at 
appropriate time intervals 300 L of the reaction mixture was withdrawn and added to 300 L of 
acetonitrile containing 0.1% trifluoroacetic acid in order to deproteinize the serum. The sample was 
sonicated, vortexed and then centrifuged for 10 min at 2150 g, the clear supernatant was filtered by 
0.45 m PTFE filters (Alltech) and analysed by RP-HPLC. All experiments were performed at least in 
triplicate. 
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The reverse-phase HPLC procedure allowed separation and quantitation of the remaining compound 
and of the products of hydrolysis (aspirin, salicylic acid, salicylate and hydroxy derivatives bearing NO-
donor or H2S-donor moieties). HPLC analyses were performed with a HP 1100 chromatograph system 
(Agilent Technologies, Palo Alto, CA, USA) equipped with a quaternary pump (model G1311A), a 
membrane degasser (G1379A), a diode-array detector (DAD) (model G1315B) integrated in the HP1100 
system. Data analysis was done using a HP ChemStation system (Agilent Technologies). The injection 
volume was 20 L (Rheodyne, Cotati, CA). The analytical column was a Nucleosil 100-5C18 Nautilus 
(250 × 4.6 mm, 5 μm particle size) (Macherey-Nagel) eluting with a flow-rate of 1.2 mL/min. The 
samples were analysed using a gradient method employing a mobile phase consisting of 
acetonitrile/water with 0.1% trifluoroacetic acid 55/45 over the first 4 min, grading to 70/30 to 6 min, 
keeping 70/30 until 15 min and then back to 55/45 to 20 min. The column effluent was monitored at 226 
nm (for compounds, aspirin and NO-donor or H2S-donor hydroxy derivatives) and at 240 nm (for 
salicylic acid and salicylates) referenced against a 600 nm wavelength. Quantitation was done by 
comparison of peak areas with standards chromatographed under the same conditions. 
Inhibition of Platelet Aggregation in vitro. 
Venous blood samples were obtained from healthy volunteers who had not taken any drug for at least 
two weeks. Volunteers, who were treated according to Helsinki protocol for biomedical 
experimentation, gave their informed consent to the use of blood samples for research purposes. Platelet 
rich plasma (PRP) was prepared by centrifugation of citrated blood at 210 g for 20 min. Aliquots 
(500 L) of PRP were added into aggregometer (Chrono-log 4902D) cuvettes and aggregation was 
recorded as increased light transmission under continuous stirring (1000 rpm) at 37 °C for 10 min after 
addition of the stimulus. Collagen at submaximal concentration (0.8-1.5 g/mL) was used as a platelet 
activator in PRP. Compounds under study were preincubated with PRP 10 min before addition of the 
stimulus (collagen). Vehicle alone (0.5% DMSO) added to PRP did not affect platelet function in 
control samples. At least 5 experiments for each compound were performed. 
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The antiaggregatory activity of tested compounds is evaluated as % inhibition of platelet aggregation 
compared to control samples. For most active compounds IC50 values could be calculated by non-linear 
regression analysis, otherwise % inhibition at maximal concentration tested (300 μM) is reported. 
Vasodilator Activities. 
Thoracic aortas were isolated from male Wistar rats weighing 180 - 200 g. As few animals as possible 
were used. The purposes and the protocols of our studies have been approved by the Ministero della 
Salute, Rome, Italy. The endothelium was removed, the vessels were cut helically and four-six strips 
were obtained from each aorta. The tissues were mounted under 1.0 g tension in organ baths containing 
30 mL of Krebs-bicarbonate buffer with the following composition (mM): NaCl 111.2, KCl 5.0, CaCl2 
2.5, MgSO4 1.2, KH2PO4 1.0, NaHCO3 12.0, glucose 11.1, maintained at 37 °C and gassed with 
95% O2-5% CO2 (pH = 7.4). The aortic strips were allowed to equilibrate for 1.5 h and then contracted 
with 1 M L-phenylephrine or 25 mM KCl. When the response to the agonist reached a plateau, 
cumulative concentrations of the vasodilating agent were added. Results are expressed as EC50 ± SEM 
(M). The effects of 1 M ODQ or 10 M glibenclamide on relaxation were evaluated in a separate 
series of experiments in which it was added 5 min before the contraction. With this protocol the 
inhibitor is preincubated for at least 30 min before the addition of the vasodilator compound. Responses 
were recorded by an isometric transducer connected to the MacLab System PowerLab. Addition of the 
drug vehicle, DMSO, had no appreciable effect on contraction level. At least 5 experiments for each 
compound were performed. 
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